Related Experiment Video
Updated: Jun 13, 2026

A Mimic of the Tumor Microenvironment: A Simple Method for Generating Enriched Cell Populations and Investigating Intercellular Communication
Published on: September 20, 2016
Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-α-dependent manner
1Joyant Pharmaceuticals Inc., Dallas, TX 75207, USA.
Abstract:
Second mitochondria-derived activator of caspase (Smac) is a mitochondrial protein released into the cytosol during apoptosis. Smac mimetics have recently been touted as a novel therapeutic to induce apoptosis in cancer cells. The ability of Smac mimetics to induce apoptosis in vitro has been shown to be dependent upon both XIAP neutralization and cancer cell autocrine tumor necrosis factor-α (TNF-α) production. In this study we provide new evidence for the utility of Smac mimetics in combination with conventional chemotherapy agents to exacerbate caspase activation and induce cancer cell death. Furthermore, we find that the combination effect is because of a multifaceted mechanism involving both inhibition of cell proliferation by the chemotherapy agents and an enhanced autocrine TNF-α feedback loop by the Smac mimetic/chemotherapy agent combination. Surprisingly, although genotoxic agents typically induce apoptosis through the mitochondrial intrinsic pathway, we show that this synergism is mediated through a TNF-α/RIP1-dependent pathway, leading to activation of the extrinsic apoptotic pathway. Finally, we report that autocrine TNF-α contributes to Smac mimetic-induced tumor regression as a single agent or in combination with chemotherapeutics in xenograft mouse models. Collectively, we provide mechanistic and applicable data to support translational studies in the use of a Smac mimetic/chemotherapy antineoplasm modality.
Insights
Smac mimetics combined with chemotherapy enhance cancer cell death by activating TNF-α signaling. This combination therapy shows promise for treating tumors by promoting apoptosis and tumor regression.
Area of Science:
- Molecular Biology
- Cancer Biology
- Pharmacology
Background:
- Second mitochondria-derived activator of caspase (Smac) is a mitochondrial protein.
- Smac mimetics are emerging therapeutics that induce apoptosis in cancer cells.
- Smac mimetic efficacy depends on XIAP neutralization and cancer cell autocrine TNF-α production.
Purpose of the Study:
- To investigate the utility of Smac mimetics in combination with conventional chemotherapy.
- To elucidate the mechanisms underlying the synergistic effects of Smac mimetic and chemotherapy combinations.
- To evaluate the therapeutic potential of Smac mimetics in preclinical cancer models.
Main Methods:
- In vitro studies assessing caspase activation and cell death.
- Analysis of autocrine TNF-α feedback loops.
- In vivo studies using xenograft mouse models.
Main Results:
- Smac mimetics combined with chemotherapy exacerbate caspase activation and induce cancer cell death.
- The combination therapy involves chemotherapy-induced cell proliferation inhibition and Smac mimetic-enhanced autocrine TNF-α signaling.
- Synergism is mediated via a TNF-α/RIP1-dependent pathway, activating the extrinsic apoptotic pathway, not the intrinsic pathway.
- Autocrine TNF-α contributes to Smac mimetic-induced tumor regression in vivo.
Conclusions:
- Smac mimetic and chemotherapy combinations offer a potent antineoplastic strategy.
- The synergistic effect is driven by the extrinsic apoptotic pathway activation.
- These findings support the translational application of Smac mimetic/chemotherapy combinations for cancer treatment.
More Related Videos
Related Concept Videos
TGF - β Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Tumor Microenvironment
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Immunotherapy
Abnormal Proliferation

